1. Spatial transcriptomics reveals unique inflammatory signatures across all anatomic locations in postoperative Crohn's disease. J Crohns Colitis. 2025 Nov 08; 19(10). Battat R, Sangiorgi B, Linggi B, Gui X, Smith MI, Mehandru S, Longman R, Lukin DJ, Scherl EJ, Qin L, Ma C, Teft W, Vande Casteele N. PMID: 41092315; PMCID: PMC12597670.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    HumansCells

  2. Identification of immune cell markers associated with ulcerative colitis histological disease activity in colonic biopsies. J Clin Pathol. 2025 Aug 18; 78(9):605-613. Lefevre PLC, Wang Z, Teft W, Zou G, Van Viegen T, Linggi B, Jairath V, Feagan BG, Pai RK, Vande Casteele N. PMID: 38418201.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans
  3. Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy. J Crohns Colitis. 2025 Jun 04; 19(6). Linggi B, Filice M, Sangiorgi B, Smith MI, Teft W, Jairath V, Ma C, Vande Casteele N. PMID: 40488582; PMCID: PMC12203003.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    HumansCellsCTClinical Trials
  4. Expert recommendations to standardize transcriptomic analysis in inflammatory bowel disease clinical trials. J Crohns Colitis. 2025 May 08; 19(5). Linggi B, Azucena S, Steere B, Verstockt B, Alsoud D, Casero D, McGovern D, Chan E, Smith MI, Ungaro F, Rieder F, Aden K, Shackelton LM, Massimino L, Neurath M, Allez M, Atreya R, Snapper SB, Raine T, Ahuja V, Haberman Y, Feagan BG, Jairath V, Vande Casteele N. PMID: 40295219.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    HumansCells
  5. Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab Therapy. Crohns Colitis 360. 2024 Oct; 6(4):otae052. Wong R, Charilaou P, Hemperly A, Qin L, Pan Y, Mathani P, Longman R, Boland BS, Dulai PS, Holmer AK, Lukin D, Singh S, Valasek MA, Sandborn WJ, Scherl E, Vande Casteele N, Battat R. PMID: 39679163; PMCID: PMC11645457.

    View in:

    PubMed   Mentions:

  6. Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease. Aliment Pharmacol Ther. 2024 Nov; 60(9):1234-1243. Chaemsupaphan T, Leong RW, Vande Casteele N, Seow CH. PMID: 39403056.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans

  7. Effect of storage time on peripheral blood mononuclear cell isolation from blood collected in vacutainer CPT™ tubes. J Immunol Methods. 2023 08; 519:113504. Linggi B, Cremer J, Wang Z, Van Viegen T, Vermeire S, Lefevre P, Shackelton LM, Jairath V, Teft W, Vande Casteele N, Verstockt B. PMID: 37257687.

    View in:

    PubMed

       Mentions:

    3  

       Fields: 

       Translation:

    HumansCells
  8. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023 07; 20(7):433-446. Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, Vande Casteele N, Alimentiv Translational Research Consortium (ATRC). PMID: 37069321; PMCID: PMC10958371.

    View in:

    PubMed

       Mentions:

    90  

       Fields: 

       Translation:

    Humans

  9. Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel. Nat Rev Gastroenterol Hepatol. 2022 Jun; 19(6):410. Verstockt B, Vetrano S, Salas A, Nayeri S, Duijvestein M, Vande Casteele N, Alimentiv Translational Research Consortium (ATRC). PMID: 35256808.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       

  10. Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases. JAMA. 2022 04 19; 327(15):1506. Vande Casteele N. PMID: 35438733.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  11. Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open. 2022 04 01; 12(4):e057656. Papamichael K, Jairath V, Zou G, Cohen B, Ritter T, Sands B, Siegel C, Valentine J, Smith M, Vande Casteele N, Dubinsky M, Cheifetz A. PMID: 35365535; PMCID: PMC8977745.

    View in:

    PubMed

       Mentions:

    12  

       Fields: 

       Translation:

    HumansCTClinical Trials

  12. Utilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis. Inflamm Bowel Dis. 2022 03 30; 28(4):539-546. Vande Casteele N, Leighton JA, Pasha SF, Cusimano F, Mookhoek A, Hagen CE, Rosty C, Pai RK, Pai RK. PMID: 34106256.

    View in:

    PubMed

       Mentions:

    25  

       Fields: 

       Translation:

    HumansCells
  13. Application of Artificial Intelligence to Clinical Practice in Inflammatory Bowel Disease - What the Clinician Needs to Know. J Crohns Colitis. 2022 Mar 14; 16(3):460-471. Chen D, Fulmer C, Gordon IO, Syed S, Stidham RW, Vande Casteele N, Qin Y, Falloon K, Cohen BL, Wyllie R, Rieder F. PMID: 34558619; PMCID: PMC8919817.

    View in:

    PubMed

       Mentions:

    3  

       Fields: 

       Translation:

    Humans
  14. Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2022 Feb 23; 16(2):224-243. Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Vande Casteele N, Hanzel J, Crowley E, Battat R, Dulai PS, Singh S, D'Haens G, Sandborn W, Feagan BG, Ma C, Jairath V. PMID: 34309658.

    View in:

    PubMed

       Mentions:

    9  

       Fields: 

       Translation:

    Humans

  15. Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2022 06; 19(6):351-366. Verstockt B, Vetrano S, Salas A, Nayeri S, Duijvestein M, Vande Casteele N, Alimentiv Translational Research Consortium (ATRC). PMID: 35165437.

    View in:

    PubMed

       Mentions:

    65  

       Fields: 

       Translation:

    Humans
  16. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022 02; 7(2):171-185. Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L, International Consortium for Therapeutic Drug Monitoring. PMID: 35026171; PMCID: PMC10187071.

    View in:

    PubMed

       Mentions:

    62  

       Fields: 

       Translation:

    Humans
  17. A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. BioDrugs. 2022 Jan; 36(1):85-93. Lefevre PLC, Dulai PS, Wang Z, Guizzetti L, Feagan BG, Pop A, Yassine M, Shackelton LM, Jairath V, Sandborn WJ, Vande Casteele N. PMID: 34951696; PMCID: PMC9826742.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    HumansCTClinical Trials

  18. Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis. Aliment Pharmacol Ther. 2022 01; 55(2):178-190. Ma C, MacDonald JK, Nguyen TM, Chang J, Vande Casteele N, Feagan BG, Jairath V. PMID: 34821404.

    View in:

    PubMed

       Mentions:

    5  

       Fields: 

       Translation:

    Humans
  19. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BioDrugs. 2021 Nov; 35(6):715-733. Bots SJ, Parker CE, Brandse JF, Löwenberg M, Feagan BG, Sandborn WJ, Jairath V, D'Haens G, Vande Casteele N. PMID: 34797516; PMCID: PMC9826743.

    View in:

    PubMed

       Mentions:

    39  

       Fields: 

       Translation:

    Humans
  20. Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis. Sci Rep. 2021 09 14; 11(1):18243. Linggi B, Jairath V, Zou G, Shackelton LM, McGovern DPB, Salas A, Verstockt B, Silverberg MS, Nayeri S, Feagan BG, Vande Casteele N. PMID: 34521888; PMCID: PMC8440637.

    View in:

    PubMed

       Mentions:

    18  

       Fields: 

       Translation:

    HumansCells
  21. Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice. Inflamm Bowel Dis. 2021 07 27; 27(8):1346-1355. Vande Casteele N, Feagan BG, Wolf DC, Pop A, Yassine M, Horst SN, Ritter TE, Sandborn WJ. PMID: 33051647; PMCID: PMC8314098.

    View in:

    PubMed

       Mentions:

    8  

       Fields: 

       Translation:

    Humans
  22. Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. BMJ Open. 2021 07 01; 11(7):e043921. Gu B, De Gregorio M, Pipicella JL, Vande Casteele N, Andrews JM, Begun J, Connell W, D'Souza B, Gholamrezaei A, Hart A, Liew D, Radford-Smith G, Rimola J, Sutherland T, Toong C, Woods R, Wu Y, Xuan W, Williams AJ, Ng W, Ding NS, Connor S. PMID: 34210720; PMCID: PMC8252869.

    View in:

    PubMed

       Mentions:

    4  

       Fields: 

       Translation:

    HumansCTClinical Trials
  23. Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis. Am J Gastroenterol. 2021 05 01; 116(5):1007-1014. Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. PMID: 33929379; PMCID: PMC8095681.

    View in:

    PubMed

       Mentions:

    36  

       Fields: 

       Translation:

    Humans

  24. Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. Dig Dis Sci. 2022 04; 67(4):1128-1155. Ma C, MacDonald JK, Nguyen TM, Vande Casteele N, Linggi B, Lefevre P, Wang Y, Feagan BG, Jairath V. PMID: 33770330.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans
  25. An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology. 2021 06; 160(7):2291-2302. Ma C, Sedano R, Almradi A, Vande Casteele N, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R, Sands BE, Rosty C, Dubinsky MC, Rieder F, Harpaz N, Abreu MT, Bryant RV, Lauwers GY, Kirsch R, Valasek MA, Crowley E, Sandborn WJ, Feagan BG, Pai RK, Jairath V. PMID: 33610533; PMCID: PMC8851891.

    View in:

    PubMed

       Mentions:

    52  

       Fields: 

       Translation:

    Humans

  26. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs. 2021 Feb; 81(3):333-347. Hanzel J, Ma C, Casteele NV, Khanna R, Jairath V, Feagan BG. PMID: 33400241.

    View in:

    PubMed

       Mentions:

    18  

       Fields: 

       Translation:

    Humans
  27. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor. Clin Gastroenterol Hepatol. 2022 02; 20(2):465-467.e2. Vande Casteele N, Abreu MT, Flier S, Papamichael K, Rieder F, Silverberg MS, Khanna R, Okada L, Yang L, Jain A, Cheifetz AS. PMID: 33421628; PMCID: PMC8257758.

    View in:

    PubMed

       Mentions:

    12  

       Fields: 

       Translation:

    Humans

  28. Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. Clin Gastroenterol Hepatol. 2022 04; 20(4):727-736.e2. Khanna R, Ma C, Jairath V, Vande Casteele N, Zou G, Feagan BG. PMID: 33338657.

    View in:

    PubMed

       Mentions:

    10  

       Fields: 

       Translation:

    Humans

  29. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. Curr Opin Pharmacol. 2020 12; 55:99-109. Hernandez-Rocha C, Vande Casteele N. PMID: 33207299.

    View in:

    PubMed

       Mentions:

    6  

       Fields: 

       Translation:

    Humans
  30. Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. Ther Adv Gastroenterol. 2020; 13:1756284820971214. Holmer AK, Battat R, Dulai PS, Vande Casteele N, Nguyen N, Jain A, Miralles A, Neill J, Le H, Singh S, Rivera-Nieves J, Sandborn WJ, Boland BS. PMID: 33240396; PMCID: PMC7675888.

    View in:

    PubMed

       Mentions:

    6  
  31. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2021 10; 66(10):3563-3569. Yarur AJ, Deepak P, Vande Casteele N, Battat R, Jain A, Okada L, Osterman M, Regueiro M. PMID: 33089483; PMCID: PMC8449757.

    View in:

    PubMed

       Mentions:

    5  

       Fields: 

       Translation:

    Humans
  32. Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Aliment Pharmacol Ther. 2020 11; 52(10):1574-1582. Battat R, Vande Casteele N, Pai RK, Wang Z, Zou G, McDonald JWD, Duijvestein M, Jeyarajah J, Parker CE, Van Viegen T, Nelson SA, Boland BS, Singh S, Dulai PS, Valasek MA, Feagan BG, Jairath V, Sandborn WJ. PMID: 32981088; PMCID: PMC8007067.

    View in:

    PubMed

       Mentions:

    6  

       Fields: 

       Translation:

    Humans
  33. Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions. Inflamm Bowel Dis. 2020 09 18; 26(10):1498-1508. Porter AC, Aubrecht J, Birch C, Braun J, Cuff C, Dasgupta S, Gale JD, Hinton R, Hoffmann SC, Honig G, Linggi B, Schito M, Casteele NV, Sauer JM. PMID: 32840322; PMCID: PMC7500523.

    View in:

    PubMed

       Mentions:

    8  

       Fields: 

       Translation:

    Humans
  34. Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. Br J Clin Pharmacol. 2021 03; 87(3):1141-1149. Vande Casteele N, Jakate A, McNamee B, Sandborn WJ. PMID: 32671846; PMCID: PMC9328660.

    View in:

    PubMed

       Mentions:

    3  

       Fields: 

       Translation:

    Humans
  35. Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. Aliment Pharmacol Ther. 2020 08; 52(3):568-569. Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. PMID: 32656846.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  36. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2020 Aug 01; 14(Supplement_2):S725-S736. Lefevre PLC, Vande Casteele N. PMID: 32160283; PMCID: PMC7395308.

    View in:

    PubMed

       Mentions:

    20  

       Fields: 

       Translation:

    Humans
  37. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. Am J Gastroenterol. 2020 06; 115(6):885-894. Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, D'Haens G, Feagan BG, Sandborn WJ, Jairath V, Singh S. PMID: 32384283; PMCID: PMC7274901.

    View in:

    PubMed

       Mentions:

    14  

       Fields: 

       Translation:

    Humans
  38. Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. Clin Gastroenterol Hepatol. 2021 06; 19(6):1209-1217.e2. Vande Casteele N, Jairath V, Jeyarajah J, Dulai PS, Singh S, Shackelton LM, Feagan BG, Sandborn WJ. PMID: 32376505.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    Humans
  39. Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 03; 19(3):511-518.e6. Battat R, Hemperly A, Truong S, Whitmire N, Boland BS, Dulai PS, Holmer AK, Nguyen NH, Singh S, Vande Casteele N, Sandborn WJ. PMID: 32348905; PMCID: PMC7606215.

    View in:

    PubMed

       Mentions:

    25  

       Fields: 

       Translation:

    Humans
  40. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther. 2020 06; 51(11):1031-1038. Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. PMID: 32329532; PMCID: PMC8032452.

    View in:

    PubMed

       Mentions:

    68  

       Fields: 

       Translation:

    Humans
  41. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. Clin Transl Sci. 2020 07; 13(4):743-751. Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Casteele N. PMID: 32100960; PMCID: PMC7359948.

    View in:

    PubMed

       Mentions:

    4  

       Fields: 

       Translation:

    Humans
  42. Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn's Disease. J Can Assoc Gastroenterol. 2021 Apr; 4(2):73-77. Verdon C, Vande Casteele N, Heron V, Germain P, Afif W. PMID: 33855264; PMCID: PMC8023823.

    View in:

    PubMed

       Mentions:

    12  
  43. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020 06; 17(6):323-337. Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, Vetrano S, Vande Casteele N. PMID: 32203403.

    View in:

    PubMed

       Mentions:

    291  

       Fields: 

       Translation:

    HumansCells
  44. Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 04; 19(4):839-841.e2. Papamichael K, Clarke WT, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, Siegel CA, Irving PM, Cheifetz AS. PMID: 32147594; PMCID: PMC7483237.

    View in:

    PubMed

       Mentions:

    10  

       Fields: 

       Translation:

    Humans
  45. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 12; 18(13):2952-2961.e8. Dulai PS, Singh S, Vande Casteele N, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C. PMID: 32062041; PMCID: PMC7899124.

    View in:

    PubMed

       Mentions:

    38  

       Fields: 

       Translation:

    Humans
  46. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther. 2020 02; 51(4):435-445. Dulai PS, Singh S, Jairath V, Ma C, Narula N, Vande Casteele N, Peyrin-Biroulet L, Vermeire S, D'Haens G, Feagan BG, Sandborn WJ. PMID: 31755121; PMCID: PMC6989392.

    View in:

    PubMed

       Mentions:

    14  

       Fields: 

       Translation:

    Humans
  47. Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Inflamm Bowel Dis. 2019 10 18; 25(11):e143-e145. Clarke WT, Papamichael K, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, Siegel CA, Irving PM, Cheifetz AS. PMID: 31559417.

    View in:

    PubMed

       Mentions:

    8  

       Fields: 

       Translation:

    Humans

  48. Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine. BioDrugs. 2019 Oct; 33(5):453-468. Lefevre PLC, Shackelton LM, Vande Casteele N. PMID: 31301024.

    View in:

    PubMed

       Mentions:

    6  

       Fields: 

       Translation:

    Humans

  49. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. J Crohns Colitis. 2019 Sep 27; 13(10):1248-1256. Vande Casteele N, Baert F, Bian S, Dreesen E, Compernolle G, Van Assche G, Ferrante M, Vermeire S, Gils A. PMID: 30820530.

    View in:

    PubMed

       Mentions:

    18  

       Fields: 

       Translation:

    Humans
  50. Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Crohns Colitis. 2019 Sep 19; 13(9):1201-1216. Ma C, Panaccione NR, Nguyen TM, Guizzetti L, Parker CE, Hussein IM, Vande Casteele N, Khanna R, Dulai PS, Singh S, Feagan BG, Jairath V. PMID: 31111881; PMCID: PMC6751339.

    View in:

    PubMed

       Mentions:

    11  

       Fields: 

       Translation:

    Humans
  51. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019 10; 50(8):848-857. Singh S, Dulai PS, Vande Casteele N, Battat R, Fumery M, Boland BS, Sandborn WJ. PMID: 31483522; PMCID: PMC7083298.

    View in:

    PubMed

       Mentions:

    31  

       Fields: 

       Translation:

    Humans
  52. Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. Clin Gastroenterol Hepatol. 2020 May; 18(5):1121-1132.e2. Duijvestein M, Jeyarajah J, Guizzetti L, Zou G, Parker CE, van Viegen T, VandeCasteele N, Khanna R, Van Der Aa A, Sandborn WJ, Feagan BG, D'Haens GR, Jairath V. PMID: 31442599.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    Humans

  53. Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location. Authors' reply. Aliment Pharmacol Ther. 2019 07; 50(1):104-105. Vande Casteele N, Jairath V. PMID: 31184386.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    HumansCells

  54. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther. 2019 07; 50(1):5-23. Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande Casteele N, Khanna R, Panaccione R, Feagan BG, Jairath V. PMID: 31119766.

    View in:

    PubMed

       Mentions:

    43  

       Fields: 

       Translation:

    Humans
  55. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother. 2019; 15(10):2482-2490. Battat R, Dulai PS, Jairath V, Vande Casteele N. PMID: 30897022; PMCID: PMC6816403.

    View in:

    PubMed

       Mentions:

    15  

       Fields: 

       Translation:

    Humans
  56. Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol. 2019 05; 114(5):733-745. Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Vande Casteele N, Pai RK, Feagan BG, Sandborn WJ, Jairath V. PMID: 30694863.

    View in:

    PubMed

       Mentions:

    27  

       Fields: 

       Translation:

    Humans

  57. View in:

    PubMed

       Mentions:

    79  

       Fields: 

       Translation:

    HumansCells
  58. Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. Aliment Pharmacol Ther. 2019 06; 49(11):1401-1409. Novak G, Stevens T, Van Viegen T, Bossuyt P, Štabuc B, Jeyarajah J, Zou G, Gaemers IC, McKee TD, Fu F, Shackelton LM, Khanna R, van den Brink GR, Sandborn WJ, Feagan BG, Pai RK, Jairath V, Vande Casteele N, D'Haens G. PMID: 30983024.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    HumansCells
  59. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 08; 17(9):1655-1668.e3. Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. PMID: 30928454; PMCID: PMC6661210.

    View in:

    PubMed

       Mentions:

    144  

       Fields: 

       Translation:

    Humans

  60. Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease. Best Pract Res Clin Gastroenterol. 2019 Feb - Apr; 38-39:101606. Ma C, Jairath V, Vande Casteele N. PMID: 31327403.

    View in:

    PubMed

       Mentions:

    17  

       Fields: 

       Translation:

    Humans

  61. Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2019 Mar; 17(1):127-145. Ma C, Battat R, Jairath V, Vande Casteele N. PMID: 30680599.

    View in:

    PubMed

       Mentions:

    19  
  62. Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. Inflamm Bowel Dis. 2019 01 10; 25(2):410-420. Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS. PMID: 30295781; PMCID: PMC6327228.

    View in:

    PubMed

       Mentions:

    22  

       Fields: 

       Translation:

    Humans

  63. Use of Precision Medicine in Clinical Trials in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 01 10; 25(2):213-216. Khanna R, Vande Casteele N. PMID: 30256949.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    Humans
  64. Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. Clin Pharmacokinet. 2018 12; 57(12):1593-1601. Vande Casteele N, Oyamada J, Shimizu C, Best BM, Capparelli EV, Tremoulet AH, Burns JC. PMID: 29623653.

    View in:

    PubMed

       Mentions:

    10  

       Fields: 

       Translation:

    Humans
  65. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 11 29; 24(12):2527-2542. Hemperly A, Sandborn WJ, Vande Casteele N. PMID: 29788338; PMCID: PMC11187819.

    View in:

    PubMed

       Mentions:

    19  

       Fields: 

       Translation:

    Humans

  66. Customized Use of Anti-Tumour Necrosis Factor-α Therapy During Pregnancy. J Crohns Colitis. 2018 11 15; 12(11):1379-1380. Seow CH, Vande Casteele N, Panaccione R. PMID: 29905838.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  67. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2019 12; 17(13):2722-2730.e4. Battat R, Duijvestein M, Vande Casteele N, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M, Jain A, Sandborn WJ, Boland BS. PMID: 30448597; PMCID: PMC6520204.

    View in:

    PubMed

       Mentions:

    19  

       Fields: 

       Translation:

    Humans
  68. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1814-1821.e1. Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ. PMID: 30613004.

    View in:

    PubMed

       Mentions:

    34  

       Fields: 

       Translation:

    Humans
  69. Definitions of response and remission for the Robarts Histopathology Index. Gut. 2019 11; 68(11):2101-2102. Pai RK, Khanna R, D'Haens GR, Sandborn WJ, Jeyarajah J, Feagan BG, Vande Casteele N, Jairath V. PMID: 30366909.

    View in:

    PubMed

       Mentions:

    17  

       Fields: 

       Translation:

    Humans
  70. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2461-2467. Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. PMID: 29788240; PMCID: PMC6693035.

    View in:

    PubMed

       Mentions:

    34  

       Fields: 

       Translation:

    Humans

  71. Additional Stability Testing of Cryopreserved Intestinal Biopsies for Downstream Flow Cytometric Analysis. J Immunol Methods. 2019 11; 474:112517. Vande Casteele N, Wildenberg ME. PMID: 30201393.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans

  72. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointest Endosc. 2018 12; 88(6):887-898. Pai RK, Jairath V, Vande Casteele N, Rieder F, Parker CE, Lauwers GY. PMID: 30142351.

    View in:

    PubMed

       Mentions:

    52  

       Fields: 

       Translation:

    Humans
  73. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. 2019 07; 68(7):1162-1168. Jairath V, Peyrin-Biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-Bressenot A, Stitt LW, Shackelton LM, Khanna R, D'Haens GR, Sandborn WJ, Olson A, Feagan BG, Pai RK. PMID: 30076171.

    View in:

    PubMed

       Mentions:

    19  

       Fields: 

       Translation:

    HumansCTClinical Trials

  74. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet. 2018 08; 57(8):929-942. Hemperly A, Vande Casteele N. PMID: 29330783.

    View in:

    PubMed

       Mentions:

    76  

       Fields: 

       Translation:

    Humans

  75. Evaluation of the effect of storage condition on cell extraction and flow cytometric analysis from intestinal biopsies. J Immunol Methods. 2018 08; 459:50-54. Wildenberg ME, Duijvestein M, Westera L, van Viegen T, Buskens CJ, van der Bilt JDW, Stitt L, Jairath V, Feagan BG, Vande Casteele N. PMID: 29772249.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    HumansCells
  76. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis. 2018 May 25; 12(6):635-643. Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. PMID: 29370397; PMCID: PMC7189966.

    View in:

    PubMed

       Mentions:

    119  

       Fields: 

       Translation:

    Humans
  77. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018; 13(5):e0195123. Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ. PMID: 29771924; PMCID: PMC5957395.

    View in:

    PubMed

       Mentions:

    136  

       Fields: 

       Translation:

    Humans
  78. Corrigendum: Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2018 04 27; 12(5):631. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. PMID: 29566131.

    View in:

    PubMed   Mentions:

       Fields: 

       
  79. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther. 2018 06; 47(12):1578-1596. Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. PMID: 29696670.

    View in:

    PubMed

       Mentions:

    12  

       Fields: 

       Translation:

    Humans
  80. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018 06; 47(11):1472-1479. Kurnool S, Nguyen NH, Proudfoot J, Dulai PS, Boland BS, Vande Casteele N, Evans E, Grunvald EL, Zarrinpar A, Sandborn WJ, Singh S. PMID: 29665045; PMCID: PMC5992082.

    View in:

    PubMed

       Mentions:

    47  

       Fields: 

       Translation:

    Humans
  81. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018 09; 16(9):1407-1419.e22. Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. PMID: 29596987.

    View in:

    PubMed

       Mentions:

    23  

       Fields: 

       Translation:

    Humans
  82. Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2018 Mar; 16(1):129-146. Duijvestein M, Battat R, Vande Casteele N, D'Haens GR, Sandborn WJ, Khanna R, Jairath V, Feagan BG. PMID: 29411220.

    View in:

    PubMed

       Mentions:

    35  
  83. Putting Out the Fire in Acute Kawasaki Disease. J Pediatr. 2018 04; 195:11-13.e1. Burns JC, Vande Casteele N. PMID: 29395176.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  84. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? J Crohns Colitis. 2018 Jan 05; 12(1):105-119. Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG. PMID: 28961959.

    View in:

    PubMed

       Mentions:

    32  

       Fields: 

       Translation:

    Humans
  85. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet. 2017 12; 56(12):1513-1523. Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. PMID: 28353055.

    View in:

    PubMed

       Mentions:

    21  

       Fields: 

       Translation:

    Humans

  86. Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab. Clin Gastroenterol Hepatol. 2018 08; 16(8):1276-1283.e1. Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, Vande Casteele N, Gils A, Vermeire S. PMID: 29203225.

    View in:

    PubMed

       Mentions:

    15  

       Fields: 

       Translation:

    Humans
  87. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. Aliment Pharmacol Ther. 2018 01; 47(2):229-237. Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn WJ. PMID: 29159893; PMCID: PMC5765392.

    View in:

    PubMed

       Mentions:

    27  

       Fields: 

       Translation:

    Humans
  88. Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. Clin Transl Gastroenterol. 2017 Nov 02; 8(11):e126. Westera L, van Viegen T, Jeyarajah J, Azad A, Bilsborough J, van den Brink GR, Cremer J, Danese S, D'Haens G, Eckmann L, Faubion W, Filice M, Korf H, McGovern D, Panes J, Salas A, Sandborn WJ, Silverberg MS, Smith MI, Vermeire S, Vetrano S, Shackelton LM, Stitt L, Jairath V, Levesque BG, Spencer DM, Feagan BG, Vande Casteele N. PMID: 29095427; PMCID: PMC5717516.

    View in:

    PubMed

       Mentions:

    6  

       Fields: 

       

  89. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 12; 46(11-12):1037-1053. Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW, IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. PMID: 29027257.

    View in:

    PubMed

       Mentions:

    105  

       Fields: 

       Translation:

    Humans

  90. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis. 2017 09; 23(9):1510-1515. Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. PMID: 28816757.

    View in:

    PubMed

       Mentions:

    37  

       Fields: 

       Translation:

    Humans

  91. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology. 2017 09; 153(3):835-857.e6. Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. PMID: 28774547.

    View in:

    PubMed

       Mentions:

    104  

       Fields: 

       Translation:

    Humans

  92. Editorial: variability in adalimumab trough and peak serum concentrations. Aliment Pharmacol Ther. 2017 06; 45(11):1475-1476. Vande Casteele N, Gils A. PMID: 28474834.

    View in:

    PubMed

       Mentions:

    2  

       Fields: 

       Translation:

    Humans

  93. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. Gut. 2018 05; 67(5):818-826. Van Stappen T, Vande Casteele N, Van Assche G, Ferrante M, Vermeire S, Gils A. PMID: 28450388.

    View in:

    PubMed

       Mentions:

    43  

       Fields: 

       Translation:

    Humans

  94. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res. 2017 Aug; 34(8):1556-1563. Vande Casteele N, Khanna R. PMID: 28374338.

    View in:

    PubMed

       Mentions:

    3  

       Fields: 

       Translation:

    Humans

  95. Letter: dose optimising infliximab in acute severe ulcerative colitis - authors' reply. Aliment Pharmacol Ther. 2017 04; 45(8):1170-1171. Jairath V, Vande Casteele N, Hindryckx P. PMID: 28326588.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans

  96. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 May; 45(10):1329-1338. Seow CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, Tanyingoh D, Bindra G, Stewart MJ, Beck PL, Kaplan GG, Ghosh S, Panaccione R. PMID: 28318043.

    View in:

    PubMed

       Mentions:

    26  

       Fields: 

       Translation:

    HumansCTClinical Trials

  97. Erratum to: Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. Drugs. 2017 03; 77(4):379. Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Jairath V, Feagan BG. PMID: 28247265.

    View in:

    PubMed   Mentions:

       Fields: 

       

  98. Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. Drugs. 2017 03; 77(4):363-377. Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Jairath V, Feagan BG. PMID: 28233275.

    View in:

    PubMed

       Mentions:

    24  

       Fields: 

       Translation:

    HumansAnimals
  99. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017 03; 45(5):617-630. Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. PMID: 28074618; PMCID: PMC6658182.

    View in:

    PubMed

       Mentions:

    35  

       Fields: 

       Translation:

    Humans
  100. Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation. Clin Transl Gastroenterol. 2016 Dec 08; 7(12):e206. Van Stappen T, Bollen L, Vande Casteele N, Papamichael K, Van Assche G, Ferrante M, Vermeire S, Gils A. PMID: 27929524; PMCID: PMC5288585.

    View in:

    PubMed

       Mentions:

    22  

       Fields: 

       
  101. Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2017 02; 11(2):246-255. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. PMID: 27487793.

    View in:

    PubMed

       Mentions:

    9  

       Fields: 

       Translation:

    Humans

  102. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation. Clin Gastroenterol Hepatol. 2016 12; 14(12):1685-1696. Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL. PMID: 27215364.

    View in:

    PubMed

       Mentions:

    34  

       Fields: 

       Translation:

    Humans
  103. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. Clin Gastroenterol Hepatol. 2016 09; 14(9):1302-9. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. PMID: 27189916.

    View in:

    PubMed

       Mentions:

    17  

       Fields: 

       Translation:

    Humans

  104. Efficacy and Safety Profile of Anti-tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons. Clin Ther. 2016 Jun; 38(6):1342-1358.e6. Miligkos M, Papamichael K, Vande Casteele N, Mantzaris GJ, Gils A, Levesque BG, Zintzaras E. PMID: 27091732.

    View in:

    PubMed

       Mentions:

    16  

       Fields: 

       Translation:

    Humans
  105. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Apr; 22(4):998-1009. Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. PMID: 26835982; PMCID: PMC5953904.

    View in:

    PubMed

       Mentions:

    10  

       Fields: 

       Translation:

    Humans

  106. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. J Crohns Colitis. 2016 Sep; 10(9):1015-23. Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S. PMID: 27022161.

    View in:

    PubMed

       Mentions:

    42  

       Fields: 

       Translation:

    Humans
  107. Efficient Early Drug Development for Ulcerative Colitis. Gastroenterology. 2016 05; 150(5):1056-1060. Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG. PMID: 27018491.

    View in:

    PubMed

       Mentions:

    8  

       Fields: 

       Translation:

    HumansAnimals
  108. Assays for measurement of TNF antagonists in practice. Frontline Gastroenterol. 2017 Oct; 8(4):236-242. Vande Casteele N. PMID: 29067148; PMCID: PMC5641847.

    View in:

    PubMed

       Mentions:

    25  

  109. Thromboembolism as an important complication of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2016 Jan; 28(1):1-7. Bollen L, Vande Casteele N, Ballet V, van Assche G, Ferrante M, Vermeire S, Gils A. PMID: 26513610.

    View in:

    PubMed

       Mentions:

    25  

       Fields: 

       Translation:

    Humans

  110. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study. Ann Intern Med. 2016 Jan 05; 164(1):10-22. Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V, Ferrante M, Noman M, Assche GV, Rutgeerts P, van den Oord JJ, Gils A, Segaert S, Vermeire S. PMID: 26641955.

    View in:

    PubMed

       Mentions:

    44  

       Fields: 

       Translation:

    Humans

  111. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):543-9. Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. PMID: 26681486.

    View in:

    PubMed

       Mentions:

    65  

       Fields: 

       Translation:

    Humans
  112. The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile. Inflamm Bowel Dis. 2015 Nov; 21(11):2540-8. Bollen L, Vande Casteele N, Peeters M, Van Assche G, Ferrante M, Van Moerkercke W, Declerck P, Vermeire S, Gils A. PMID: 26313696; PMCID: PMC4623846.

    View in:

    PubMed

       Mentions:

    5  

       Fields: 

       Translation:

    Humans

  113. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015 Nov; 42(10):1158-69. Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N. PMID: 26365281.

    View in:

    PubMed

       Mentions:

    20  

       Fields: 

       Translation:

    Humans

  114. High Anti-Tumour Necrosis Factor Trough Concentrations--Only a Cost Issue or Also Hidden Dangers Ahead? J Crohns Colitis. 2015 Nov; 9(11):943-4. Vande Casteele N, Vermeire S. PMID: 26351380.

    View in:

    PubMed

       Mentions:

    1  

       Fields: 

       Translation:

    Humans

  115. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Sep; 21(9):2172-7. Van Stappen T, Billiet T, Vande Casteele N, Compernolle G, Brouwers E, Vermeire S, Gils A. PMID: 26284296.

    View in:

    PubMed

       Mentions:

    14  

       Fields: 

       Translation:

    Humans
  116. IBD: Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol. 2015 Jul; 12(7):373-4. Vande Casteele N, Sandborn WJ. PMID: 26077557.

    View in:

    PubMed

       Mentions:

    6  

       Fields: 

       Translation:

    Humans

  117. Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs? Dig Dis Sci. 2015 Sep; 60(9):2571-3. Vande Casteele N, Gils A. PMID: 25917050.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    Humans

  118. Immunogenicity to infliximab is associated with HLA-DRB1. Gut. 2015 Aug; 64(8):1344-5. Billiet T, Vande Casteele N, Van Stappen T, Princen F, Singh S, Gils A, Ferrante M, Van Assche G, Cleynen I, Vermeire S. PMID: 25876612.

    View in:

    PubMed

       Mentions:

    31  

       Fields: 

       Translation:

    Humans

  119. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut. 2016 07; 65(7):1126-31. Baert F, Kondragunta V, Lockton S, Vande Casteele N, Hauenstein S, Singh S, Karmiris K, Ferrante M, Gils A, Vermeire S. PMID: 25862647.

    View in:

    PubMed

       Mentions:

    38  

       Fields: 

       Translation:

    Humans

  120. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. J Clin Pharmacol. 2015 Mar; 55 Suppl 3:S39-50. Vande Casteele N, Gils A. PMID: 25707962.

    View in:

    PubMed

       Mentions:

    24  

       Fields: 

       Translation:

    Humans

  121. Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2015 Mar; 21(3):570-8. Bollen L, Vande Casteele N, Peeters M, Bessonov K, Van Steen K, Rutgeerts P, Ferrante M, Hoylaerts MF, Vermeire S, Gils A. PMID: 25659086.

    View in:

    PubMed

       Mentions:

    16  

       Fields: 

       Translation:

    Humans

  122. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015 Jun; 148(7):1320-9.e3. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S. PMID: 25724455.

    View in:

    PubMed

       Mentions:

    302  

       Fields: 

       Translation:

    Humans
  123. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015 Jan; 21(1):182-97. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. PMID: 25222660.

    View in:

    PubMed

       Mentions:

    120  

       Fields: 

       Translation:

    Humans

  124. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1103-10. Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, Princen F, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. PMID: 25478919.

    View in:

    PubMed

       Mentions:

    22  

       Fields: 

       Translation:

    Humans
  125. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2015 Oct; 64(10):1539-45. Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR, Rutgeerts PJ, Gils A, Sandborn WJ, Vermeire S, Feagan BG. PMID: 25336114; PMCID: PMC4602247.

    View in:

    PubMed

       Mentions:

    107  

       Fields: 

       Translation:

    Humans

  126. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther. 2014 Dec; 40(11-12):1324-32. Baert F, Vande Casteele N, Tops S, Noman M, Van Assche G, Rutgeerts P, Gils A, Vermeire S, Ferrante M. PMID: 25277873.

    View in:

    PubMed

       Mentions:

    27  

       Fields: 

       Translation:

    Humans
  127. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit. 2014 Oct; 36(5):669-73. Gils A, Vande Casteele N, Poppe R, Van de Wouwer M, Compernolle G, Peeters M, Brouwers E, Vermeire S, Geukens N, Declerck PJ. PMID: 24906181; PMCID: PMC4218762.

    View in:

    PubMed

       Mentions:

    11  

       Fields: 

       Translation:

    HumansCells

  128. An update on anti-TNF agents in ulcerative colitis. Gastroenterol Clin North Am. 2014 Sep; 43(3):479-94. Samaan MA, Bagi P, Vande Casteele N, D'Haens GR, Levesque BG. PMID: 25110254.

    View in:

    PubMed

       Mentions:

    7  

       Fields: 

       Translation:

    Humans

  129. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):531-8. Arias MT, Vande Casteele N, Vermeire S, de Buck van Overstraeten A, Billiet T, Baert F, Wolthuis A, Van Assche G, Noman M, Hoffman I, D'Hoore A, Gils A, Rutgeerts P, Ferrante M. PMID: 25117777.

    View in:

    PubMed

       Mentions:

    81  

       Fields: 

       Translation:

    Humans

  130. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):514-521.e4. Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G. PMID: 25066841.

    View in:

    PubMed

       Mentions:

    46  

       Fields: 

       Translation:

    Humans
  131. Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed. Clin Gastroenterol Hepatol. 2014 Nov; 12(11):1894-6. Vande Casteele N, Sandborn WJ. PMID: 24951843.

    View in:

    PubMed   Mentions:

       Fields: 

       Translation:

    Humans
  132. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014 Apr; 16(4):378. Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, Levesque BG. PMID: 24595615.

    View in:

    PubMed

       Mentions:

    29  

       Fields: 

       Translation:

    Humans

  133. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol. 2014 Sep; 12(9):1474-81.e2; quiz e91. Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S, Lockton S, Rutgeerts P, Vermeire S. PMID: 24486408.

    View in:

    PubMed

       Mentions:

    42  

       Fields: 

       Translation:

    Humans

  134. Letter: dry blood spots for anti-TNF treatment monitoring in IBD. Aliment Pharmacol Ther. 2013 May; 37(10):1024-5. Vande Casteele N, Brecx S, Declerck P, Ferrante M, Rutgeerts P, Vermeire S, Gils A. PMID: 23590542.

    View in:

    PubMed

       Mentions:

    3  

       Fields: 

       Translation:

    Humans

  135. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013 Jun; 108(6):962-71. Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S. PMID: 23419382.

    View in:

    PubMed

       Mentions:

    131  

       Fields: 

       Translation:

    Humans

  136. Letter: detection of infliximab levels and anti-infliximab antibodies--comparison of three different assays; authors' reply. Aliment Pharmacol Ther. 2013 Jan; 37(2):282. Buurman DJ, Vande Casteele N, Sturkenboom MG, Kleibeuker JH, Vermeire S, van der Kleij D, Rispens T, Gils A, Dijkstra G. PMID: 23252783.

    View in:

    PubMed

       Mentions:

    4  

       Fields: 

       Translation:

    Humans

  137. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012 Oct; 36(8):765-71. Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, van der Kleij D, Gils A, Dijkstra G. PMID: 22928581.

    View in:

    PubMed

       Mentions:

    62  

       Fields: 

       Translation:

    Humans

  138. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 2012 Feb; 61(2):229-34. Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P. PMID: 21948942.

    View in:

    PubMed

       Mentions:

    58  

       Fields: 

       Translation:

    Humans

  139. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay. Aliment Pharmacol Ther. 2011 Aug; 34(3):401-3; author reply 404-5. Vande Casteele N, Breynaert C, Vermeire S, Rutgeerts PJ, Gils A, Van Assche G. PMID: 21726254.

    View in:

    PubMed

       Mentions:

    4  

       Fields: 

       Translation:

    Humans

  140. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut. 2012 Feb; 61(2):321; author reply 322. Vande Casteele N, Ballet V, Van Assche G, Rutgeerts P, Vermeire S, Gils A. PMID: 21330576.

    View in:

    PubMed

       Mentions:

    15  

       Fields: 

       Translation:

    Humans